We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GE Healthcare Launches MabSelect SuRe™ LX Affinity Chromatography Medium
Product News

GE Healthcare Launches MabSelect SuRe™ LX Affinity Chromatography Medium

GE Healthcare Launches MabSelect SuRe™ LX Affinity Chromatography Medium
Product News

GE Healthcare Launches MabSelect SuRe™ LX Affinity Chromatography Medium


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "GE Healthcare Launches MabSelect SuRe™ LX Affinity Chromatography Medium"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GE Healthcare extends the MabSelect™ family with MabSelect SuRe LX, a protein A-derived affinity medium designed to promote efficient processing of high-titer bioreactor feeds. MabSelect SuRe LX has enhanced alkaline stability and exceptional dynamic binding capacity that exceeds similar high-flow agarose media such as MabSelect SuRe.

The highly-rigid base matrix facilitates the use of higher bed heights and high flow rates, which reduces cycle time and provides flexibility in process design. Additionally, higher dynamic binding capacity and bed heights enable the use of small-diameter columns, thus reducing equipment footprint.

MabSelect SuRe LX is optimized for high dynamic binding capacity at extended residence times. For example, at six minutes residence time, its capacity for human and monoclonal IgG is approximately 60mg/l, which is more than 20% higher than its companion product MabSelect SuRe.

The benefits of MabSelect Sure LX include:

• Exceptional binding capacity at longer residence time and high flow rates for processing large volumes of high-titer feeds quickly and efficiently

• Enhanced alkaline-tolerance for cleaning-in-place with 0.1 M to 0.5 M NaOH, prolonging medium lifetime to over 300 purification cycles, thus enhancing process economy

• Enhanced protease-resistant protein A ligand reduces leakages

• Generic elution conditions for different MAbs promote the use of platform purifications

The ever-growing demand for MAbs as biopharmaceuticals and the increase in antibody titer has driven the development of MabSelect SuRe LX. MAbs can now be processed faster and with improved process economy.

Advertisement